Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Publication year range
1.
Rinsho Ketsueki ; 65(4): 231-236, 2024.
Article in Japanese | MEDLINE | ID: mdl-38684432

ABSTRACT

A 69-year-old woman was referred to our hospital due to hyperleukocytosis. We diagnosed acute myeloid leukemia and started induction therapy with the CAG regimen (aclarubicin, cytarabine and filgrastim). However, the patient was refractory to the initial treatment and developed quadriplegia, and a cerebrospinal fluid (CSF) test showed elevated blasts. We then performed intrathecal chemotherapy, and the number of blasts in CSF gradually decreased. But only two cycles of intrathecal therapy were possible due to severe methotrexate-induced mucositis. The leukemia cells had fms-like kinase 3-internal tandem duplication (FLT3-ITD), so we started treatment with oral gilteritinib. The patient then achieved hematological complete remission. Her paralysis was also resolving, and the CSF was clear of blasts for more than 6 months. Some reports show that gilteritinib may penetrate the CNS, and this case also supports the effectiveness of gilteritinib on CNS leukemia.


Subject(s)
Aniline Compounds , Leukemia, Myeloid, Acute , Pyrazines , Humans , Aged , Female , Leukemia, Myeloid, Acute/drug therapy , Pyrazines/administration & dosage , Pyrazines/therapeutic use , Aniline Compounds/therapeutic use , Central Nervous System Neoplasms/drug therapy , fms-Like Tyrosine Kinase 3 , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...